Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Triple Negative Breast Cancer Malignancies”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Very early researchStudy completedNCT01467310
What this trial is testing

Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212

Who this might be right for
Breast Cancer
UNC Lineberger Comprehensive Cancer Center 15
Not applicableStudy completedNCT04540224
What this trial is testing

The Relationship Between the Differences in Blood Cytokine Values in Breast Cancers.

Who this might be right for
Breast Cancer
Istanbul Training and Research Hospital 78
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07721259
What this trial is testing

A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden

Who this might be right for
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+1 more
University of Washington 60
Not applicableLooking for participantsNCT06259162
What this trial is testing

LAG3 Expression in Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast CancerImmune Checkpoint Inhibitor
Samsung Medical Center 128
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05522491
What this trial is testing

Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer

Who this might be right for
Solid Tumor
Hebei Medical University Fourth Hospital 30
Testing effectiveness (Phase 2)Ended earlyNCT01151449
What this trial is testing

Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer

Who this might be right for
Estrogen Receptor-negative Breast CancerHER2-negative Breast CancerMale Breast Cancer+7 more
National Cancer Institute (NCI) 6
Early research (Phase 1)Active Not RecruitingNCT04052555
What this trial is testing

Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer

Who this might be right for
Bilateral Breast CarcinomaHER2-Negative Breast CarcinomaLocalized Breast Carcinoma+2 more
National Cancer Institute (NCI) 42
Testing effectiveness (Phase 2)UnknownNCT05546255
What this trial is testing

Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
Chinese Academy of Medical Sciences 40
Testing effectiveness (Phase 2)Looking for participantsNCT06238921
What this trial is testing

Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases

Who this might be right for
Breast CancerTriple Negative Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute 31
Testing effectiveness (Phase 2)Active Not RecruitingNCT03449108
What this trial is testing

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

Who this might be right for
Bone SarcomaDedifferentiated ChondrosarcomaGiant Cell Tumor of Bone+13 more
M.D. Anderson Cancer Center 30
Large-scale testing (Phase 3)Study completedNCT04085276
What this trial is testing

Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment

Who this might be right for
Triple-Negative Breast Cancer
Shanghai Junshi Bioscience Co., Ltd. 531
Not applicableUnknownNCT06261918
What this trial is testing

Transcriptional and Epimetabolic Profile of Breast Carcinoma With Luminal or HER2+ or Locally Advanced Triple-negative Histotype in Patients With/Without Previous Clinical History of Metabolic Syndrome

Who this might be right for
Breast CancerMetabolic Syndrome
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 120
Testing effectiveness (Phase 2)Active Not RecruitingNCT02734290
What this trial is testing

Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
Providence Health & Services 29
Large-scale testing (Phase 3)Study completedNCT00130533
What this trial is testing

Maintenance Treatment With Capecitabine Versus Observation in Breast Cancer Patients

Who this might be right for
Breast Cancer
Spanish Breast Cancer Research Group 876
Testing effectiveness (Phase 2)Study completedNCT03098550
What this trial is testing

Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread

Who this might be right for
Advanced Cancer
Bristol-Myers Squibb 105
Testing effectiveness (Phase 2)UnknownNCT02681562
What this trial is testing

Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients

Who this might be right for
Breast CancerTriple Negative Breast Cancer
Istituti Ospitalieri di Cremona 45
Not applicableUnknownNCT04362462
What this trial is testing

Molecular Profiling After Neoadjuvant Chemotherapy for Triple-negative Breast Cancer

Who this might be right for
Triple-negative Breast Cancer
Texas Tech University Health Sciences Center, El Paso 120
Testing effectiveness (Phase 2)Looking for participantsNCT04159818
What this trial is testing

Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients

Who this might be right for
Metastatic Breast Cancer
The Netherlands Cancer Institute 52
Testing effectiveness (Phase 2)Active Not RecruitingNCT02883062
What this trial is testing

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

Who this might be right for
Invasive Breast CarcinomaStage II Breast Cancer AJCC v6 and v7Stage III Breast Cancer AJCC v7+1 more
National Cancer Institute (NCI) 67
Early research (Phase 1)Ended earlyNCT04060342
What this trial is testing

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

Who this might be right for
Pancreatic AdenocarcinomaEsophageal AdenocarcinomaEsophageal Squamous Cell Carcinoma+11 more
GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. 61
Next Page